Currently Viewing:
Newsroom
Currently Reading
PCT Just as Effective as MASCC for Predicting Serious Complications in Febrile Neutropenia
January 18, 2019 – Jaime Rosenberg
CMS Expands VBID in Medicare Advantage, Increases Risk Sharing in Part D
January 18, 2019 – Allison Inserro
Tracking Medicaid Expansion
January 18, 2019 – AJMC Staff
This Week in Managed Care: January 18, 2019
January 18, 2019
USPSTF Releases Draft Recommendation on Drugs to Lower Risk of Breast Cancer
January 18, 2019 – Samantha DiGrande
CMS Proposes Changes to ACA Premiums, Reducing Tax Credits
January 18, 2019 – Allison Inserro
5 Findings From the January 2019 Health IT Issue of AJMC®
January 18, 2019 – Christina Mattina
AJMC® in the Press, January 18, 2019
January 18, 2019 – AJMC Staff
What We're Reading: Price Hikes for Older Drugs; FDA Shifts Resources; Opioids and Birth Defects
January 18, 2019 – AJMC Staff

AJMC® in the Press, November 9, 2018

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
OBR Oncology’s Thursday daily newsfeed included an article from The American Journal of Managed Care® (AJMC®). The article, “Azar Announces Mandatory Oncology Payment Model is Coming,” covered the HHS secretary’s announcement that the administration will revisit mandatory models that it had previously scrapped in cardiac care and that the time had come for “exploring new and improved episode-based models in other areas, including radiation oncology.”

AJMC®’s The Center for Biosimilars®’ article “FDA Approves Coherus’ Pegfilgrastim Biosimilar, Udenyca” was highlighted in OBR Oncology's Monday daily newsfeed. The article reported that, after previous US regulatory setbacks, the manufacturer had gained approval for its biosimilar, referencing Neulasta, to decrease the incidence of infection, as manifested by febrile neutropenia, in patients receiving myelosuppressive chemotherapy associated with a clinically significant incidence of febrile neutropenia.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!